ASX:GTGPharmaceuticals, Biotechnology & Life SciencesLife Sciences Tools & Services

GENETIC TECHNOLOGIES ORD

$0.039
+$0.000 (+0.00%)
Day Range
$0.000 - $0.000
52 Week Range
$0.000 - $0.000
Volume
0.00
Avg Volume (10D)
0.00
Market Cap
$52.08M
Price Chart
Market Statistics
Open$0.039
Previous Close$0.039
Day High$0.000
Day Low$0.000
00
Valuation
Market Cap52.08M
Shares Outstanding1.34B
Trading Activity
Volume0.00
Value Traded0.00
Performance
Latest News
Market wrap: Australia bucks global trend as weak energy and miners deflate the ASX 200
Hot Topics

Market wrap: Australia bucks global trend as weak energy and miners deflate the ASX 200

Once again, Australia’s relative lack of technology stocks has seen the local market fail to keep pace with strong offshore leads. On Friday after all three major US equity benchmarks reset new highs, weakness in mining and energy stocks in Australia dragged the ASX 200 index down by 0.2% or 11.4 points, to 7770.6 points. […]

6 min read
John Beveridge
John Beveridge
Genetic Technologies unveils GeneType test for unprecedented disease risk assessment
Biotechnology

Genetic Technologies unveils GeneType test for unprecedented disease risk assessment

Molecular diagnostics company Genetic Technologies (ASX: GTG) has announced a major breakthrough in risk assessment tests for serious diseases. The new GeneType technology builds on the success of the company’s comprehensive hereditary breast and ovarian cancer test. The innovation will be a world first in identifying more than 200 high-penetrant genes to unlock the hereditary […]

1 min read
Colin Hay
Colin Hay
Genetic Technologies to launch world-first comprehensive risk assessment test for breast and ovarian cancer
Biotechnology

Genetic Technologies to launch world-first comprehensive risk assessment test for breast and ovarian cancer

A ground-breaking comprehensive risk assessment test is set to be introduced by Genetic Technologies (ASX: GTG) to assesses the likelihood that a woman will develop breast and/or ovarian cancer, whether as a result of a hereditary genetic mutation or the much more prevalent familial or sporadic cancer. The test integrates Genetic Technologies’ patented and proprietary GeneType platform […]

2 min read
Filip Karinja
Filip Karinja
ASX biotech stocks benefiting from the COVID-19 story
Biotechnology

ASX biotech stocks benefiting from the COVID-19 story

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]

4 min read
Tim Boreham
Tim Boreham